Additional US patent to be granted regarding IntelliGel
The United States Patent and Trade Mark Office (USPTO) has communicated its intention to grant a new US patent in the portfolio licensed to Redwood Pharma from Broda International LLC. A new US patent will, when granted, provide enhanced patent protection in the United States for the so-called IntelliGel platform, which is used, inter alia, in the development of Redwood Pharmas RP101 product.
“We are very pleased that the protection of RP101, our drug for the treatment of chronic dry eye in women, and for other ophthalmological products, will be strengthened. As soon as the patent is granted, it will expand the protection of possible hydrogel compositions and innovative ways of obtaining them. Redwood Pharma secures the protection through an integrated IP strategy implemented by the company and by the licensor Broda International. We thank our licensing partners for their continued innovations and for continuing to seek IP protection, “says CEO Martin Vidaeus.
IntelliGel is Redwood Pharma’s exclusive technology for delivering drug to the front of the eye with a new hydrogel based on poloxamers and water. IntelliGel is applied as eye drop and gels on contact with the eye. This transparent, lubricating, reversible thermogel can increase the bioavailability of the active substance, as the gel holds the drug in the eye for longer. This, in turn, allows for a reduction of the amount of active substance administered, a reduction in the number of doses and possible side effects related to the active substance. IntelliGel is currently used in dermatological products sold commercially in the US and China. IntelliGel can be used for prescription products as well as for OTC products.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at February 23, 2017.
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com